Delivery Order SPE2DB20D1100-SPE2DB25FE5V9
- Not listed
- The Defense Logistics Agency awarded a $4,074.30 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Veltassa 8.4 GM powder packets (30 count). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 31, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Veltassa 8.4 GM Powder Packet (30-count) with a ceiling value of $1,358.10. This is a firm fixed price delivery order with no set-aside designation, meaning the award was made through open competition. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of August 29, 2025. This delivery order is issued...
- The Defense Logistics Agency awarded a $2,565.83 delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Veltassa 8.4 GM powder packets (30-count units). This is a firm fixed-price contract with an ultimate completion date of August 26, 2025, and represents a non-set-aside competitive award. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major pharmaceutical...
- The Defense Logistics Agency awarded a $1,424.40 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Veltassa 8.4 GM powder packets (30-count). This is a firm fixed price contract with an ultimate completion date of September 5, 2025, and represents a non-set-aside, competitively awarded transaction. The contract is to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Veltassa is a potassium-binding agent used in the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Veltassa 8.4 GM Powder Packet in a quantity of 30 units, with a ceiling value of $2,716.20. This is a firm fixed-price delivery order with an ultimate completion date of August 12, 2025, and represents a non-competitive, non-set-aside award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order on September 10, 2025, for Veltassa 8.4 GM powder packets (30-count) with a ceiling value of $2,037.15 under firm fixed pricing. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of September 11, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency has awarded a delivery order to AmerisourceBergen Drug Corp for Veltassa 8.4 GM powder packets (30-count) under a firm fixed-price contract valued at $2,469.40, with an ultimate completion date of September 2, 2025. This non-competitive delivery order represents a procurement of pharmaceutical products for military healthcare needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $1,358.10 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Veltassa 8.4 gm powder packets (30-count units). This is a non-set-aside competitive award with an ultimate completion date of July 28, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran...
- The Defense Logistics Agency awarded a $7,533.98 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Veltassa 8.4 GM powder packets (30-count units). This is a firm fixed-price, non-set-aside contract with a completion date of August 15, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Veltassa is a potassium-binding medication used to treat hyperkalemia, a condition characterized by elevated potassium levels in the blood....
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,921.77 for VELTASSA 8.4 GM powder packets (30-count) on August 11, 2025, with completion scheduled for August 12, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The order will be fulfilled from...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE5V9Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,863.59 to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Veltassa 8.4 GM Powder Packet in quantities of 30 units. This is a firm fixed price delivery order with an ultimate completion date of September 11, 2025, and was awarded competitively without set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive pharmaceutical supply vehicle supporting military healthcare programs globally, enabling AmerisourceBergen to deliver a broad range of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains. Veltassa, a potassium-binding medication used in treating hyperkalemia, represents one of the specialized pharmaceutical products supplied through this expansive contract vehicle to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.9k | 9/10/25 |